Report ID : 10094780 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Montelukast Intermediate Market Highlights Over 2022 – 2031
The global montelukast intermediate market is estimated to grow at a CAGR of ~ 4% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increase in respiratory problems such as asthma. Asthma affected approximately 262 million people in 2019, and 461,000 people died as a consequence of it, according to the World Health Organization. Moreover, there have been deteriorating effects on the health of people considering the increase in air pollution. Every minute, 13 people are killed by air pollution, as per the WHO. Montelukast is used in drugs for the treatment of asthma, allergic rhinitis, and others, owing to which there has been a surge in the growth of the global montelukast intermediate market. Furthermore, pharmaceutical companies have increased their demand for montelukast for the production of drugs, which is also anticipated to contribute to market growth in the coming years.
GET A SAMPLE COPY OF THIS REPORT
The global montelukast intermediate market is segmented by application into allergic rhinitis, bronchospasm, urticaria, and asthma. Out of these, the asthma segment is anticipated to hold the largest share in the global montelukast intermediate market over the forecast period owing to the increase in asthma cases. Furthermore, asthma is one of the most common prevalent chronic diseases in children, and proper medication can control the symptoms of asthma and allow them to lead normal life. Moreover, there has been increase in pollution that is contributing to the growth of the asthma segment.
Global Montelukast Intermediate Market Regional Synopsis
Regionally, the global montelukast intermediate market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of an increase in respiratory illnesses, primarily caused due to the surge in air pollution, followed by the rise in the number of aged people. According to the WHO, the Asia Pacific region accounts for one-third of all global air pollution deaths. Furthermore, being exposed to a toxic environment can result in serious health risks such as respiratory problems, asthma, and others. Moreover, approximately 30 % of the total population in Japan is over 60 years. The aged population is more prone to respiratory problems and is expected to increase the growth of the montelukast intermediate market in the region.
Market Segmentation
Our in-depth analysis of the global montelukast intermediate market includes the following segments:
By Application
-
Allergic Rhinitis
-
Bronchospasm
-
Urticaria
-
Asthma
By End-Users
-
Laboratories
-
Biotechnology & Pharmaceutical Companies
-
Others
By Type
-
Good Manufacturing Practice
-
Non-Good Manufacturing Practice
Growth Drivers and Challenges Impacting the Growth of the Global Montelukast Intermediate Market
Growth Drivers
-
Increase in the respiratory problems
-
Increase in the demand for the production of pharmaceutical drugs
Challenges
-
High cost for montelukast intermediate
-
Stringent regulation related to the use of ingredients in the drugs
Key Companies Dominating the Global Montelukast Intermediate Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global montelukast intermediate market that are included in our report are ORTIN LABORATORIES LIMITED, Lonza Group Ltd., Merck & Co., Inc., Rahway, NJ, USA, Cipla Inc., Spark Therapeutics, Inc., uniQure N.V., Oxford Biomedica, MASSACHUSETTS BIOTECHNOLOGY COUNCIL, FinVector Oy, MANUS AKTTEVA BIOPHARMA LLP, and others.
Latest Developments in the Global Montelukast Intermediate Market:
-
31 March 2022: Lonza Group Ltd., announced its membership in the International Pharmaceutical Aerosol Consortium on Regulation & Science. The company has partnered with other industry leaders for the advancement of inhalation technologies.
-
19 June 2020: Merck & Co., Inc., Rahway, NJ, USA, announced the complete acquisition of Themis, a company that focuses on infectious disease vaccines and immune modulation therapies.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
